New Alzheimer’s Treatment

New Alzheimer’s Treatment

Neurology | Faculty of Medicine
Share Story Related Content Add to my report

A unique new treatment for Alzheimer’s Disease could put Canada—and UBC—in the history books for helping to prevent this killer disease that now affects one in 11 Canadians over the age of 65.

UBC Faculty of Medicine neuroscientist Neil Cashman, a member of the Brain Research Centre at UBC and Vancouver Coastal Health, has developed an immune-based treatment that targets the catalyst in triggering Alzheimer’s—a small clump of toxic protein molecules that forms plaques in the brain. While previous treatments targeted the plaques themselves, this new treatment aims to eradicate the toxin before it can cause any damage. The catch? The toxic version of the protein only lives a short time.

But, by producing antibodies that specifically attach to the toxic protein, Dr. Cashman, who is now working with Canadian biopharmaceutical company Cangene to develop a treatment, has created an effective early diagnostic for the disease, and has laid the groundwork for the development of a preventative vaccine.

“This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic,” says J.P. Heale, Associate Director of UBC’s University-Industry Liaison Office. “The partnerships developed to advance Dr. Cashman’s outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance.”

 

 

Related Content

“This is an all-Canadian solution and an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance.” – J.P. Heale, Associate Director of UBC’s University-Industry Liaison Office

Associated Commitment

Research Excellence
Dr. Neil Cashman in his lab Credit: Martin Dee

Associated Campus

Vancouver Campus

Twitter

RT @Ronan_Denyer: Very pleased to share an updated version of this review article written w/ @laboyd47 and @Greenhouse_Lab now published @T…
4 days ago.
RT @Ronan_Denyer: Pleased to share a preprint of my “pandemic review” written with @Greenhouse_Lab and @laboyd47! We review TMS studies inv…
22 Jul, 22
RT @bkgreeley: New pub now live in @ASNRehab out of @UBC_BrainLab: https://t.co/5OnVukhYNV . This one was fun! We found that high levels of…
9 May, 22
PhD student @Ronan_Denyer is currently recruiting for an online behavioural experiment delivered through your web b… https://t.co/5d6VYb1Tmr
10 Nov, 21
Read more about Cristina's @CRubino11 doctoral work on uncovering unseen links between visual and motor impairments… https://t.co/IVDbI3zp5b
28 Oct, 20
Congratulations @AttardKatie - the BBL is so proud 👏👏👏 https://t.co/ulQa8jUT0W
17 Jun, 20
RT @HELP_UBC: What is happening to our brains right now? Find out this Friday when @kimschon chats with @UBC_BrainLab Director, Dr. Lara Bo…
16 Jun, 20
RT @Ronan_Denyer: Happy to (finally) share our new paper @JNeuroimaging examining myelin/math development in youth! @UBC_BrainLab #myelin…
15 Jun, 20
We are very excited to share that several BBL trainees will be presenting their work at #OHBM2020 in Montreal 🇨🇦. I… https://t.co/BQgv6TcbRj
23 Feb, 20
RT @DMCBrainHealth: “I don’t want other people to live through what I had to live through,” says Thalia. “That’s why my research is focused…
21 Feb, 20